TG1050 Expected to Enter Clinic in Mid-2015
Strasbourg, France, April 23, 2015 – Transgene SA (Euronext: TNG) today announced that new pre-clinical data with TG1050, an immunotherapy being developed for the treatment of chronic hepatitis B, were presented at The International Liver Congress™ 2015, the 50th Congress of the European Association for the Study of the Liver (EASL) in Vienna, Austria. The TG1050 data were presented as part of a Liver Immunology session in an oral presentation entitled: TG1050, A Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-persistent Mouse Models (Abstract O031).
The data presented today demonstrate the antiviral potential of TG1050 in a persistent hepatitis B virus (HBV) in vivo model. In this model, TG1050 was shown to significantly reduce circulating HBV DNA, to reduce the circulating HBV surface antigen (HBsAg), and to trigger seroconversion to HBsAg (i.e., to develop anti-HBsAg antibodies). The development of anti-HBsAg antibodies has been associated with HBV cure.
The presentation is available on Transgene’s website in the “Our Pipeline/Publications” section at http://www.transgene.fr/?page_id=10487#TG1050.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.16||-0.32%||3 255|